I see where you’re coming from, but isn’t the point that this isn’t really a phase 1 drug, but it’s considered so due to the reformulation. PK/PD is identical and the FDA agree it’s the same based on recent announcements. So assuming there are no precipitation issues regardless of red tape how can it still be valued like a phase 1 drug. I’m not saying it won’t be, I mean that’s my concern at the end of the day that the market continues to incorrectly value the opportunity.
RAC - Crystal ball gazing, page-25
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.66 |
Change
-0.030(1.78%) |
Mkt cap ! $284.6M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.66 | $16.21K | 9.731K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 969 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 917 | 1 |
View Market Depth
| Last trade - 11.37am 07/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |